Insider Selling: Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Sells 25,000 Shares of Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Krystal Biotech Stock Up 3.0 %

Shares of NASDAQ KRYS opened at $201.58 on Monday. Krystal Biotech, Inc. has a 12-month low of $93.95 and a 12-month high of $219.34. The firm’s 50-day simple moving average is $196.03 and its 200 day simple moving average is $178.75. The company has a market cap of $5.79 billion, a price-to-earnings ratio of 107.80 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.50 by $0.03. The company had revenue of $70.28 million for the quarter, compared to analyst estimates of $65.27 million. Krystal Biotech had a net margin of 63.73% and a return on equity of 1.99%. Krystal Biotech’s quarterly revenue was up 70283900.0% on a year-over-year basis. During the same period in the prior year, the business earned ($1.25) earnings per share. On average, equities analysts expect that Krystal Biotech, Inc. will post 3.13 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Stifel Nicolaus lifted their price objective on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Citigroup reiterated a “neutral” rating and issued a $204.00 price target (up from $195.00) on shares of Krystal Biotech in a research report on Tuesday, August 6th. Chardan Capital lifted their price objective on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a report on Monday, August 5th. Evercore ISI upped their target price on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. Finally, William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $196.75.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Jamison Private Wealth Management Inc. bought a new stake in shares of Krystal Biotech during the second quarter worth $28,000. GAMMA Investing LLC raised its holdings in Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after purchasing an additional 93 shares during the last quarter. Key Financial Inc acquired a new position in Krystal Biotech during the 2nd quarter valued at about $28,000. Blue Trust Inc. boosted its stake in shares of Krystal Biotech by 2,328.6% in the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after purchasing an additional 163 shares during the last quarter. Finally, Quest Partners LLC acquired a new stake in shares of Krystal Biotech during the 2nd quarter worth approximately $71,000. 86.29% of the stock is currently owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).